Considering HER2 as one of the well-known biomarkers in the cancer field, and published articles regarding serumlevels of HER2, in this paper we tried to highlight the issue that most studies don’t stratify the HER-2 concentrationof individuals in terms of gender. In this brief survey, healthy individuals with no prior non-communicable diseaseswere categorized as males (n=34) and females (n=43), and all samples were evaluated for plasma HER-2 levelsat once. Surprisingly, the plasma level of HER-2 of healthy male individuals (mean= 2.28 ± 0.21 ng/mL) wassignificantly (P<0.0001) higher than the plasma level of HER-2 of healthy females (mean: 0.06 ± 0.09 ng/mL),with no overlap. Therefore, we suggest that more studies are required to re-check the cutoff values for HER-2plasma levels based on gender since the clinical implications of a unique HER-2 cutoff for both genders may beseriously concerning.
